NASDAQ · CSII
Healthcare · Medical - Devices
$20.00
Up+$0.03 (+0.15%)
Updated Aug 22, 2026, 7:57 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CSII does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CSII.
CSII research
Company profile and research snapshot.
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 21, 2022 | Barclays | Equal-Weight | — |
| May 5, 2022 | SVB Leerink | Outperform | — |
| Feb 4, 2022 | SVB Leerink | Outperform | — |
| Nov 17, 2021 | Needham | Hold | — |
| Nov 10, 2021 | Guggenheim | Neutral | — |
No generated briefing is available yet.
Zacks Investment Research · Apr 5, 2023
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
Zacks Investment Research · Mar 23, 2023
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Benzinga · Feb 13, 2023
Needham has downgraded Surmodics Inc (NASDAQ: SRDX) to Hold from Buy. In January, Surmodics received a letter from the FDA regarding its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). The letter stated that certain information within two general categories—biocompatibility and labeling—must be added by an amendment to the company's PMA application to place it in approvable form. The company is now preparing a request for feedback from the FDA, and management expects to receive the FDA's response in May. Assuming that Surmodics is required to conduct additional animal testing, which would take a ...Full story available on Benzinga.com
Zacks Investment Research · Feb 13, 2023
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CSII.
No results
No recent SID articles mention CSII.
